Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production

Blood

Volumn 101, Issue 8, 2003, Pages 3029-3036

  Mizutani, Akio ^b   Okajima, Kenji ^a   Uchiba, Mitsuhiro ^b   Isobe, Hirotaka ^b   Harada, Naoaki ^b   Mizutani, Sachiko ^b   Noguchi, Takayuki ^b  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; DANSYLGLUTAMYLGLYCYLARGINYL CHLOROMETHYL KETONE; ILOPROST; INDOMETACIN; KETONE DERIVATIVE; MYELOPEROXIDASE; PROSTACYCLIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTITHROMBIN III; DANSYL GLUTAMYL GLYCYL ARGINYL CHLOROMETHYL KETONE TREATED FACTOR XA; DANSYL-GLUTAMYL-GLYCYL-ARGINYL CHLOROMETHYL KETONE-TREATED FACTOR XA; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE CHLOROMETHYL KETONE; PEROXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HISTOPATHOLOGY; ISCHEMIA; KIDNEY BLOOD FLOW; KIDNEY INJURY; LEUKOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; THROMBIN TIME; TISSUE LEVEL; ANIMAL; BIOSYNTHESIS; CAPILLARY PERMEABILITY; DRUG SCREENING; GENETICS; GERMFREE ANIMAL; IMMUNOLOGY; KIDNEY; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; PATHOLOGY; VASCULAR ENDOTHELIUM; VASCULARIZATION; WISTAR RAT;

6-KETOPROSTAGLANDIN F1 ALPHA; AMINO ACID CHLOROMETHYL KETONES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTITHROMBIN III; CAPILLARY PERMEABILITY; DRUG EVALUATION, PRECLINICAL; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; FACTOR XA; ILOPROST; INDOMETHACIN; ISCHEMIA; KIDNEY; LYMPHOCYTE ACTIVATION; MALE; PEROXIDASE; RATS; RATS, WISTAR; REPERFUSION INJURY; SPECIFIC PATHOGEN-FREE ORGANISMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037944105     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-08-2406     Document Type: Article

References (41)

1. Rosenberg RD. Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism. Am J Med. 1989;87:2S-9S.
2. Lane DA, Bayston T, Olds RJ, et al. Antithrombin mutation database: 2nd (1997) update. Thromb Haemost. 1997;77:197-211.
3. Okajima K, Abe H, Maeda S, et al. Antithrombin III Nagasaki (Ser116-Pro): a heterozygous variant with defective heparin binding associated with thrombosis. Blood. 1993;81:1300-1305.
4. Emerson TE Jr, Fournel MA, Redens TB, Taylor FB Jr. Efficacy of antithrombin III supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia. Am J Med. 1989;87:27S-33S.
5. Inthorn D, Hoffmann JN, Hartl WH, Muhlbayer D, Jochum M. Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock. 1997;8:328-334.
6. Inthorn D, Hoffmann JN, Hartl WH, Muhlbayer D, Jochum M. Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock. 1998;10:90-96.
7. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol. 1996;270:L921-L930.
8. D'Acquisto F, Sautebin L, Iuvone T, Di Rosa M, Carnuccio R. Prostaglandins prevent inducible nitric oxide synthase protein expression by inhibiting nuclear factor-κB activation in J774 macrophages. FEBS Lett. 1998;440:76-80.
9. Oh-ishi S, Utsunomiya I, Yamamoto T, Komuro Y, Hara Y. Effects of prostaglandins and cyclic AMP on cytokine production in rat leukocytes. Eur J Pharmacol. 1996;300:255-259.
10. Ollivier V, Parry GC, Cobb RR, de Prost D, Mackman N. Elevated cyclic AMP inhibits NF-κB-mediated transcription in human monocytic cells and endothelial cells. J Biol Chem. 1996;271:20828-20835.
11. Uchiba M, Okajima K, Murakami K. Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Thromb Res. 1998;89:233-241.
12. Isobe H, Okajima K, Uchiba M, Harada N, Okabe H. Antithrombin prevents endotoxin-induced hypotension by inhibiting the induction of nitric oxide synthase in rats. Blood. 2002;99:1638-1645.
13. Dunzendorfers S, Kaneider N, Rabensteiner A, et al. Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. Blood. 2001;97:1079-1085.
14. Souter PJ, Thomas S, Hubbard AR, Poole S, Romisch J, Gray E. Antithrombin inhibits lipopolysaccaharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med. 2001;29:134-139.
15. Oelschläger C, Römisch J, Staubitz H, et al. Antithrombin III inhibits nuclear factor κB activation in human monocytes and vascular endothelial cells. Blood. 2002;99:4015-4020.
16. Okajima K. Regulation of inflammatory responses by natural anticoagulants. Immunol Rev. 2001;184:258-274.
17. Miller-Andersson M, Borg H, Andersson LO. Purification of antithrombin III by affinity chromatography. Thromb Res. 1974;5:439-452.
18. Heger A, Grunert T, Schulz P, Josic D, Buchacher A. Separation of active and inactive forms of human antithrombin by heparin affinity chromatography. Thromb Res. 2002;106:157-164.
19. Nesheim ME, Kettner C, Shaw E, Mann KG. Cofactor dependence of factor Xa incorporation into the prothrombinase complex. J Biol Chem. 1981;256:6537-6540.
20. Bajaj SP, Rapaport SI, Prodanos CA. A simplified procedure for purification of human prothrombin, factor IX and factor X. Prep Biochem. 1981;11:397-412.
21. Morita T, Jackson CM. Localization of the structural difference between bovine blood coagulation factors X1 and X2 to tyrosine 18 in the activation peptide. J Biol Chem. 1986;261:4008-4014.
22. Mann KG. Membrane-bound enzyme complexes in blood coagulation. In: Spaet TH, ed. Progress in Hemostasis and Thrombosis, Vol 7. New York, NY: Grune & Stratton; 1984:1-24.
23. Karp GI, Marcum JA, Rosenberg RD. The role of tryptophan residues in heparin-antithrombin interactions. Arch Biochem Biophys. 1984;233:712-720.
24. Rabb H, Mendiola CC, Saba SR, et al. Antibodies to ICAM-1 protect kidneys in severe ischemic reperfusion injury. Biochem Biophys Res Commun. 1995;211:67-73.
25. Mizutani A, Okajima K, Uchiba M, Noguchi T. Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood. 2000;95:3781-3787.
26. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Effects of antithrombin III (AT III) and Trp49-modified AT III on plasma level of 6-keto PGF1 α in rats. Thromb Res. 1995;80:201-208.
27. Kelly KJ, Williams WW Jr, Colvin RB, et al. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest. 1996;97:1056-1063.
28. Chiao H, Kohda Y, McLeroy P, Craig L, Housini I, Star RA. α-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats. J Clin Invest. 1997;99:1165-1172.
29. Ramos E, Closa D, Hotter G, Rosello-Catafau J, Gelpi E, Fernandez-Cruz L. The impact of arterialization on prostanoid generation after liver transplantation in the rat. Transplantation. 1994;58:140-144.
30. Okano J, Shiota G, Kawasaki H. Protective action of hepatocyte growth factor for acute liver injury caused by D-galactosamine in transgenic mice. Hepatology. 1997;26:1241-1249.
31. Taoka Y, Okajima K, Uchiba M, et al. Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting activation of leukocytes. J Neurosci. 1998;18:1393-1398.
32. Watanabe K, Suematsu M, Iida M, et al. Effect of rat CINC/gro, a member of the interleukin-8 family, on leukocytes in microcirculation of the rat mesentery. Exp Mol Pathol. 1992;56:60-69.
33. Kawabata K, Suzuki M, Sugitani M, Imaki K, Toda M, Miyamoto T. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun. 1991;177:814-829.
34. Ivanyi B, Ormos J, Lantos J. Tubulointerstitial inflammation, cast formation, and renal parenchymal damage in experimental pyelonephritis. Am J Pathol. 1983;113:300-308.
35. Druid H, Enestrom S, Rammer L. Effect of anticoagulation upon nephron obstruction in experimental acute renal ischaemic renal failure; a morphological study. Int J Exp Pathol. 1998;79:55-66.
36. Altavilla D, Saitta A, Guarini S, et al. Oxidative stress causes nuclear factor-κ B activation in acute hypovolemic hemorrhagic shock. Free Radic Biol Med. 2001;30:1055-1066.
37. Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev. 1978;30:293-331.
38. Singbarti K, Forlow SB, Ley K. Platelet, but not endothelial, P-selectin is critical for neutrophil-mediated acute postischemic renal failure. FASEB J. 2001;15:2337-2344.
39. Uchiba M, Okajima K. Antithrombin does not directly promote the endothelial production of prostacyclin in cultured endothelial cells. Thromb Haemost. 2001;86:722-723.
40. Harada N, Okajima K, Uchiba M, Katsuragi T. Ischemia/reperfusion-induced increase in the hepatic level of prostacyclin is mainly mediated by activation of capsaicin-sensitive sensory neurons in rats. J Lab Clin Med. 2002;139:218-226.
41. Harada N, Okajima K, Uchiba M. Antithrombin reduces ischemia/reperfusion-induced hepatic injury by increasing hepatic levels of prostacyclin via activation of capsaicin-sensitive sensory neurons in rats [abstract]. Blood. 2001;98:1084a.